E-ISSN 2231-3206 | ISSN 2320-4672
 
2024, Vol: 14, Issue: 4
14 / 4Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Authorship Declaration

Original Research

Online Publishing Date:
05 / 12 / 2020

 


Toxicities and response rate in stage II non-small cell lung cancer patients receiving paclitaxel-cisplatin – One-year observational study

Anu Chandran, Paul Mathai, Laveesh Raveendran, Varun Raghavan, Premlal K S.


Abstract
Background: The patients undergoing cancer treatment are experiencing a wide range of toxicity. This study is on cancer patients diagnosed with stage II non-small cell lung cancer (NSCLC).

Aim and Objective: The primary objective was to study and grade the various toxicities of paclitaxel (PTX) – cisplatin (CDDP) combination, using the World Health Organization’s toxicity grading scale. The secondary objective was to assess patient response to PTX-CDDP regimen.

Materials and Methods: This study is done at a tertiary care center using a prospective observational study design. CDDP-PTX regimen is followed in the department of radiotherapy for 49 patients for 1 year. For doing the statistical analysis, the data collected were entered and analyzed using a Microsoft Excel worksheet. The toxicity grading was analyzed using SPSS software.

Results: Total patients participated are 49 out of which only four were females, and 45 were male patients. The age range of patients was between 56 and 88 years. The treatment regimen followed in this study had several toxicities. Toxicity developed in the patients belongs to various categories, mainly gastrointestinal, hematological, and dermatological toxicities. Response evaluation criteria analyze the clinical response in solid tumors (RECIST criteria).

Conclusions: This study helps us to understand the wide range of adverse drug reactions; the cancer patient may go through during chemotherapy. When compared with the earlier studies, the incidence of diarrhea and renal toxicity is less due to adequate preventive measures.

Key words: Cancer Treatment; Drug Toxicity Profile; Lung Cancer; National Securities Clearing Corporation Ltd.; Paclitaxel-Cisplatin Regimen, Stage II Non-small Cell Lung Cancer; The World Health Organizations Toxicity Criteria


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Anu Chandran
Articles by Paul Mathai
Articles by Laveesh Raveendran
Articles by Varun Raghavan
Articles by Premlal K S
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Chandran A, Mathai P, Raveendran L, Raghavan V, S PK. Toxicities and response rate in stage II non-small cell lung cancer patients receiving paclitaxel-cisplatin – One-year observational study. Natl J Physiol Pharm Pharmacol. 2021; 11(1): 102-108. doi:10.5455/njppp.2021.11.11308202002412020

Web Style

Chandran A, Mathai P, Raveendran L, Raghavan V, S PK. Toxicities and response rate in stage II non-small cell lung cancer patients receiving paclitaxel-cisplatin – One-year observational study. https://www.njppp.com/?mno=27762 [Access: March 16, 2024]. doi:10.5455/njppp.2021.11.11308202002412020

AMA (American Medical Association) Style

Chandran A, Mathai P, Raveendran L, Raghavan V, S PK. Toxicities and response rate in stage II non-small cell lung cancer patients receiving paclitaxel-cisplatin – One-year observational study. Natl J Physiol Pharm Pharmacol. 2021; 11(1): 102-108. doi:10.5455/njppp.2021.11.11308202002412020


Vancouver/ICMJE Style

Chandran A, Mathai P, Raveendran L, Raghavan V, S PK. Toxicities and response rate in stage II non-small cell lung cancer patients receiving paclitaxel-cisplatin – One-year observational study. Natl J Physiol Pharm Pharmacol. (2021), [cited March 16, 2024]; 11(1): 102-108. doi:10.5455/njppp.2021.11.11308202002412020


Harvard Style

Chandran, A., Mathai, . P., Raveendran, . L., Raghavan, . V. & S, . P. K. (2021) Toxicities and response rate in stage II non-small cell lung cancer patients receiving paclitaxel-cisplatin – One-year observational study. Natl J Physiol Pharm Pharmacol, 11 (1), 102-108. doi:10.5455/njppp.2021.11.11308202002412020


Turabian Style

Chandran, Anu, Paul Mathai, Laveesh Raveendran, Varun Raghavan, and Premlal K S. 2021. Toxicities and response rate in stage II non-small cell lung cancer patients receiving paclitaxel-cisplatin – One-year observational study. National Journal of Physiology, Pharmacy and Pharmacology, 11 (1), 102-108. doi:10.5455/njppp.2021.11.11308202002412020


Chicago Style

Chandran, Anu, Paul Mathai, Laveesh Raveendran, Varun Raghavan, and Premlal K S. "Toxicities and response rate in stage II non-small cell lung cancer patients receiving paclitaxel-cisplatin – One-year observational study." National Journal of Physiology, Pharmacy and Pharmacology 11 (2021), 102-108. doi:10.5455/njppp.2021.11.11308202002412020


MLA (The Modern Language Association) Style

Chandran, Anu, Paul Mathai, Laveesh Raveendran, Varun Raghavan, and Premlal K S. "Toxicities and response rate in stage II non-small cell lung cancer patients receiving paclitaxel-cisplatin – One-year observational study." National Journal of Physiology, Pharmacy and Pharmacology 11.1 (2021), 102-108. Print. doi:10.5455/njppp.2021.11.11308202002412020


APA (American Psychological Association) Style

Chandran, A., Mathai, . P., Raveendran, . L., Raghavan, . V. & S, . P. K. (2021) Toxicities and response rate in stage II non-small cell lung cancer patients receiving paclitaxel-cisplatin – One-year observational study. National Journal of Physiology, Pharmacy and Pharmacology, 11 (1), 102-108. doi:10.5455/njppp.2021.11.11308202002412020


Author LoginReviewer LoginAbout PublisherEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

  National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal.  The journal is having open access polic ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Publisher

publishernjppp@gmail.com

 

Editorial query

editornjppp1@gmail.com

MOB - 8780040272